Efficacy of combination oral antimicrobial agents against biofilm-embedded methicillin-resistant Staphylococcus aureus

Journal of Microbiology, Immunology and Infection

Volumn 46, Issue 2, 2013, Pages 89-95

  Wu, Wen Shiann ^a   Chen, Chi Chung ^a,c   Chuang, Yin Ching ^a   Su, Bo An ^a   Chiu, Yu Hsin ^a   Hsu, Hui Jine ^a   Ko, Wen Chien ^b,e   Tang, Hung Jen ^a,d  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Biofilm; Methicillin resistant Staphylococcus aureus (MRSA); Oral antimicrobial agents

Indexed keywords

BROMINE DERIVATIVE; CRYSTAL VIOLET; FUSIDIC ACID; LINEZOLID; MINOCYCLINE; RIFAMPICIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BIOFILM; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; OPTICAL DENSITY; SURVIVAL RATE;

ANTI-INFECTIVE AGENTS; BIOFILMS; DRUG SYNERGISM; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL VIABILITY; SPECTROPHOTOMETRY;

EID: 84876157246     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2012.03.009     Document Type: Article

References (27)

1. O'Grady N.P., Alexander M., Dellinger E.P., Gerberding J.L., Heard S.O., Maki D.G., et al. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control 2002, 30:476-489.
2. Stevens D.L., Bisno A.L., Chambers H.F., Everett E.D., Dellinger P., Goldstein E.J., et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005, 41:1373-1406.
3. Zimmerli W., Trampuz A., Ochsner P.E. Prosthetic-joint infections. N Engl J Med 2004, 351:1645-1654.
4. Donlan R.M. Role of biofilms in antimicrobial resistance. ASAIO J 2000, 46:S47-S52.
5. Climo M.W., Patron R.L., Archer G.L. Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob Agents Chemother 1999, 43:1747-1753.
6. Donlan R.M., Costerton J.W. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002, 15:167-193.
7. Edmiston C.E., Goheen M.P., Seabrook G.R., Johnson C.P., Lewis B.D., Brown K.R., et al. Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices. Am J Surg 2006, 192:344-354.
8. Kaka A.S., Rueda A.M., Shelburne S.A., Hulten K., Hamill R.J., Musher D.M. Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006, 58:680-683.
9. Perlroth J., Kuo M., Tan J., Bayer A.S., Miller L.G. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 2008, 168:805-819.
10. Prince A.S. Biofilms, antimicrobial resistance, and airway infection. N Engl J Med 2002, 347:1110-1111.
11. Saginur R., Stdenis M., Ferris W., Aaron S.D., Chan F., Lee C., et al. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob Agents Chemother 2006, 50:55-61.
12. Shelburne S.A., Musher D.M., Hulten K., Ceasar H., Lu M.Y., Bhaila I., et al. In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations. Antimicrob Agents Chemother 2004, 48:4016-4019.
13. Aboltins C.A., Page M.A., Buising K.L., Jenney A.W., Daffy J.R., Choong P.F., et al. Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid. Clin Microbiol Infect 2007, 13:586-591.
14. Raad I., Chatzinikolaou I., Chaiban G., Hanna H., Hachem R., Dvorak T., et al. In vitro and ex vivo activities of minocycline and EDTA against microorganisms embedded in biofilm on catheter surfaces. Antimicrob Agents Chemother 2003, 47:3580-3585.
15. Raad I., Hanna H., Jiang Y., Dvorak T., Reitzel R., Chaiban G., et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 2007, 51:1656-1660.
16. Cheng J., Fock K.M., Chua K.L. Reversible hepatic and renal damage from rifampin overdose-a case report. Singapore Med J 1988, 29:306-308.
17. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically (M7-A7) 2006, Clinical and Laboratory Standards Institute, Clinical and Laboratory Standards Institute, Wayne, PA. 7th ed.
18. Andrews J.M. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001, 48(Suppl. 1):5-16.
19. O'Neill E., Pozzi C., Houston P., Smyth D., Humphreys H., Robinson D.A., et al. Association between methicillin susceptibility and biofilm regulation in Staphylococcus aureus isolates from device-related infections. J Clin Microbiol 2007, 45:1379-1388.
20. Kairo S.K., Bedwell J., Tyler P.C., Carter A., Corbel M.J. Development of a tetrazolium salt assay for rapid determination of viability of BCG vaccines. Vaccine 1999, 17:2423-2428.
21. Pettit R.K., Weber C.A., Kean M.J., Hoffmann H., Pettit G.R., Tan R., et al. Microplate Alamar blue assay for Staphylococcus epidermidis biofilm susceptibility testing. Antimicrob Agents Chemother 2005, 49:2612-2617.
22. Walencka E., Sadowska B., Rozalska S., Hryniewicz W., Rozalska B. Lysostaphin as a potential therapeutic agent for staphylococcal biofilm eradication. Pol J Microbiol 2005, 54:191-200.
23. Walencka E., Sadowska B., Rozalska S., Hryniewicz W., Rozalska B. Staphylococcus aureus biofilm as a target for single or repeated doses of oxacillin, vancomycin, linezolid and/or lysostaphin. Folia Microbiol (Praha) 2006, 51:381-386.
24. Kwiecinski J., Eick S., Wojcik K. Effects of tea tree (Melaleuca alternifolia) oil on Staphylococcus aureus in biofilms and stationary growth phase. Int J Antimicrob Agents 2009, 33:343-347.
25. Schillaci D., Petruso S., Sciortino V. 3,4,5,3',5'-Pentabromo-2-(2'-hydroxybenzoyl) pyrrole: a potential lead compound as anti-Gram-positive and anti-biofilm agent. Int J Antimicrob Agents 2005, 25:338-340.
26. Tang H.J., Chen C.C., Ko W.C., Yu W.L., Chiang S.R., Chuang Y.C. In vitro efficacy of antimicrobial agents against high-inoculum or biofilm-embedded meticillin-resistant Staphylococcus aureus with vancomycin minimal inhibitory concentrations equal to 2 mug/mL (VA2-MRSA). Int J Antimicrob Agents 2011, 38:46-51.
27. Ceri H., Olson M.E., Stremick C., Read R.R., Morck D., Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999, 37:1771-1776.